Samsung Biologics Co Ltd Market Cap ($46.65 Billion)
Market Cap & Net Worth: Samsung Biologics Co Ltd (207940)
Samsung Biologics Co Ltd market cap. Samsung Biologics Co Ltd (KO:207940) has a market capitalization of $46.65 Billion (₩68.83 Trillion) as of November 3, 2026. Listed on the KO stock exchange, this Korea-based company holds position #574 globally and #7 in its home market, demonstrating a 9.26% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Samsung Biologics Co Ltd's stock price ₩1487000.00 by its total outstanding shares 46290951 (46.29 Million). Also see cash efficiency ratio of Samsung Biologics Co Ltd for how efficiently the company converts equity into cash flow.
Samsung Biologics Co Ltd Market Cap History (2016–2026)
Samsung Biologics Co Ltd market cap history from 2016 to 2026. Data shows growth from $4.69 Billion to $46.65 Billion (26.50% CAGR). Check Samsung Biologics Co Ltd share price for real-time trading data and today's change.
Samsung Biologics Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Samsung Biologics Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 207940 shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.01x
Samsung Biologics Co Ltd's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.02x
Samsung Biologics Co Ltd's market cap is 0.02 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $4.69 Billion | $294.62 Billion | -$176.82 Billion | 0.02x | N/A |
| 2017 | $11.52 Billion | $464.63 Billion | -$96.97 Billion | 0.02x | N/A |
| 2018 | $12.00 Billion | $535.81 Billion | $224.11 Billion | 0.02x | 0.05x |
| 2019 | $13.44 Billion | $701.59 Billion | $202.90 Billion | 0.02x | 0.07x |
| 2020 | $25.64 Billion | $1.16 Trillion | $240.97 Billion | 0.02x | 0.11x |
| 2021 | $28.03 Billion | $1.57 Trillion | $393.59 Billion | 0.02x | 0.07x |
| 2022 | $25.76 Billion | $3.00 Trillion | $798.06 Billion | 0.01x | 0.03x |
| 2023 | $23.84 Billion | $3.69 Trillion | $857.69 Billion | 0.01x | 0.03x |
| 2024 | $29.77 Billion | $3.50 Trillion | $1.08 Trillion | 0.01x | 0.03x |
| 2025 | $31.37 Billion | $4.56 Trillion | $1.78 Trillion | 0.01x | 0.02x |
Competitor Companies of 207940 by Market Capitalization
Companies near Samsung Biologics Co Ltd in the global market cap rankings as of November 3, 2026. Also see how large is Samsung Biologics Co Ltd's balance sheet for a full breakdown of the balance sheet.
Key companies related to Samsung Biologics Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- argenx NV ADR (NASDAQ:ARGX): Ranked #583 globally with a market cap of $45.97 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #583 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
Market Capitalization of Samsung Biologics Co Ltd (2016–2026)
Market capitalization of Samsung Biologics Co Ltd from 2016 to today. Between 2016 and today, Samsung Biologics Co Ltd's market cap moved from $4.69 Billion to $ 46.65 Billion, with a yearly change of 26.50%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩46.65 Billion | +48.70% |
| 2025 | ₩31.37 Billion | +5.37% |
| 2024 | ₩29.77 Billion | +24.87% |
| 2023 | ₩23.84 Billion | -7.43% |
| 2022 | ₩25.76 Billion | -8.12% |
| 2021 | ₩28.03 Billion | +9.32% |
| 2020 | ₩25.64 Billion | +90.76% |
| 2019 | ₩13.44 Billion | +12.03% |
| 2018 | ₩12.00 Billion | +4.18% |
| 2017 | ₩11.52 Billion | +145.70% |
| 2016 | ₩4.69 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 2nd, 2026 the market cap of Samsung Biologics Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $46.65 Billion USD |
| MoneyControl | $46.65 Billion USD |
| MarketWatch | $46.65 Billion USD |
| marketcap.company | $46.65 Billion USD |
| Reuters | $46.65 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Samsung Biologics Co Ltd
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offe… Read more